Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

BioClinica Sued by Shareholder Over Sale to JLL Partners

BioClinica Inc., which provides clinical trial management services, was sued by an investor who claims the stock is undervalued in a $123 million buyout offer from New York private-equity firm JLL Partners Inc.

Because of the company’s future prospects, directors of Newtown, Pennsylvania-based BioClinica could have negotiated a higher price than the agreed-upon $7.25 a share, said James Gerson in the Delaware Chancery Court complaint made public today in Wilmington.

“Despite the persistent economic downturn throughout the United States, the company has seen a significant operating improvement in the last 12 months,” lawyers for Gerson said in the filing. They ask a judge to halt the transaction under its present terms and to award damages.

Mark Weinstein, BioClinica’s chief executive officer, didn’t immediately respond to a request seeking comment on the lawsuit.

BioClinica, which reported $83.9 million in 2011 sales, fell 3 cents to $7.23 at 12:34 p.m. in New York.

The case is Gerson v. BioClinica, CA8272, Delaware Chancery Court (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.